Sage-N Research to Sell Proteome Software’s proteomics data mining software
Sage-N Research will sell Proteome Software’s Scaffold proteomics data-mining software under an agreement announced last week. Sage-N will sell standalone versions of the Scaffold software as well as versions integrated into Sage-N’s own Sorcerer Integrated Data Appliances in North America, Europe, and Asia Pacific except Taiwan, the company said.
Financial terms of the deal were not disclosed.
The Sorcerer IDA with Scaffold provides a proteomic solution “that can handle more than 1 million spectra “with built-in automated false positive estimation using reverse sequences,” the company said in a statement.
Miraculins Includes Pancreatic, Stomach Cancer in Research Pipeline
Miraculins has expanded it product pipeline to include diagnostic research programs for pancreatic and stomach cancer, the company announced this week.
Miraculins acquired IP assets related to these diseases when it acquired Europroteme, a biomarker research company based in Germany in 2005. The company is now in the process of developing diagnostic tests for five cancers, including breast, prostate, and colorectal cancers, Miraculins said.
Thermo Sells Three Rhombix Protein Crystallization Systems to MPSI
Thermo Electron announced this week that the Membrane Protein Structure Initiative has bought three of its Rhombix protein crystallization systems.
The MPSI is a consortium of eight UK universities and institutions developing high- throughput methods for crystallization and structural determination of specific integral membrane protein targets.
The Rhombix systems will be installed at the MPSI laboratories at the University of Leeds, the University of Glasgow and the Diamond Synchroton where the Imperial College London and Diamond are jointly establishing a membrane protein laboratory.
Financial details of the purchase were not disclosed.
The Rhombix system integrates and controls liquid handling instrumentation while the Rhombix Vision hardware “automatically handles, stores, and images plates using state-of-the-art multimode imaging technologies," Thermo said in a statement.
Experimental details and automation settings are recorded and stored in a centralized database, Thermo added.
Tandem Acquires Drug Metabolite and Biomarker Profiling Company
Tandem Labs announced this week it has purchased PharmaKD, a Boston-based division of Linden Technologies providing mass spectrometry-based pharmacokinetics and pharmacodynamics for drug metabolite and biomarker profiling.
Tandem will retain key personnel, IP portfolios, proprietary informatics, scientific instruments and 7,000-square feet of operational space from PharmaKD. Tandem adds one facility to its operations as a result of the transaction, bringing the total number of Tandem facilities to three.
Financial details of the deal were not disclosed.
Based in Salt Lake City, privately-held Tandem is a CRO supporting new drug development through mass spectrometry application and immunoanalytical knowledge.
Invitrogen Gets $1.2M Contract Extension From DoD
The US Department of Defense has awarded Invitrogen a $1.2 million extension to an existing contract to use its ProtoArray protein microarray technology to research biothreats, the company announced this week.
The funding will be used to support detection and research of biothreat agents such as hemorrhagic fever and anthrax. The original $970,000 contract, awarded in January, focused on the detection and analysis of smallpox and the plague.
James Meegan, senior director of R&D at Invitrogen will direct the research.